breast cancer index (bci) (NSABP Foundation)
90
Structured Review
NSABP Foundation
breast cancer index (bci)
Breast Cancer Index (Bci), supplied by NSABP Foundation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/breast+cancer+index+(bci)/nsabp+b+18/pmc11061597__ccr___23___1977_supplementary_figure_s1_suppfs1-1-39-43
Average 90 stars, based on 1 article reviews
Breast Cancer Index (Bci), supplied by NSABP Foundation, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/breast+cancer+index+(bci)/nsabp+b+18/pmc11061597__ccr___23___1977_supplementary_figure_s1_suppfs1-1-39-43
Average 90 stars, based on 1 article reviews
breast cancer index (bci) - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Adjuvant:Article Title: Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial Article Snippet: Time-dependent Kaplan-Meier analysis based on Distant Recurrence comparing extended letrozole vs placebo in subsets of patients treated with initial adjuvant endocrine therapy with either A, AI only or B, a sequence of tamoxifen followed by AI in the overall Article Title: Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline. Article Snippet: Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: Article Title: The Utility of Breast Cancer Index (BCI) Over Clinical Prognostic Tools for Predicting the Need for Extended Endocrine Therapy: A Safety Net Hospital Experience. Article Snippet: In this retrospective chart review, we evaluated 2 tools that help providers decide which early-stage hormonereceptor positive breast cancer patients should be offered extended endocrine therapy (EET) beyond 5 years.. The Breast Cancer Index (BCI) is one such tool and allowed for more patient-specific treatment recommendations.. In our population, recommendation for EET was better correlated with high BCI benefit. Article Title: Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study. Article Snippet: Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: Sequencing:Article Title: Breast Cancer Index and Prediction of Extended Aromatase Inhibitor Therapy Benefit in Hormone Receptor-Positive Breast Cancer from the NRG Oncology/NSABP B-42 Trial Article Snippet: Time-dependent Kaplan-Meier analysis based on Distant Recurrence comparing extended letrozole vs placebo in subsets of patients treated with initial adjuvant endocrine therapy with either A, AI only or B, a sequence of tamoxifen followed by AI in the overall Article Title: Clinical Utility of Multigene Profiling Assays in Early-Stage Invasive Breast Cancer: An Ontario Health (Cancer Care Ontario) Clinical Practice Guideline. Article Snippet: Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: Article Title: The Utility of Breast Cancer Index (BCI) Over Clinical Prognostic Tools for Predicting the Need for Extended Endocrine Therapy: A Safety Net Hospital Experience. Article Snippet: In this retrospective chart review, we evaluated 2 tools that help providers decide which early-stage hormonereceptor positive breast cancer patients should be offered extended endocrine therapy (EET) beyond 5 years.. The Breast Cancer Index (BCI) is one such tool and allowed for more patient-specific treatment recommendations.. In our population, recommendation for EET was better correlated with high BCI benefit. Article Title: Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine therapy benefit: a Trans-aTTom study. Article Snippet: Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: |
